Johns Hopkins Medicine

MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) announced that the U.S. Drug Enforcement Administration has conducted a scientific review and determined that investigational cannabinoid Supera-CBD is not currently considered a controlled substance or listed chemical. The scientific review of the chemical...

In a new study, Johns Hopkins Medicine researchers tested more than a hundred topical cannabidiol (CBD) products, that are available online and at retail stores and found "significant evidence of inaccurate and misleading labeling of CBD content." In addition, some of these products...

Johns Hopkins Medicine has been exploring the healing potential of psychedelic drugs for the last 19 years. When it started in 2000, it was the first medical research institution to obtain federal approval for the research. The research has produced many studies published in peer-reviewed journals...